tagraxofusp sold brand name elzonris anticancer medication treatment blastic plasmacytoid dendritic cell neoplasm tagraxofusp fusion protein consisting interleukin fused diphtheria fusion protein readily kills cultured pdc binding receptors thereby gain entrance cells blocking cells protein synthesis due diphtheria toxin portion inhibiting eukaryotic elongation factor citation needed approved use united states european union january us food drug administration fda considers firstinclass july european medicines agency ema recommended refusal marketing authorization agency concerned due design study small number participants possible sure effective medicine treating blastic plasmacytoid dendritic cell addition medicine could cause capillary leak syndrome unpredictable potentially lifethreatening side effect due increased permeability small blood vessels led fatal november committee medicinal products human use chmp ema adopted positive opinion following reexamination procedure recommending granting marketing authorization medicinal product elzonris intended treatment blastic plasmacytoid dendritic cell neoplasm tagraxofusp approved medical use european union january antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikitagraxofusp